(a) HCA2 cells at 72 hrs after IR treatment (10 Gy) were stained with Hoechst 33342 and sorted according to size and structure (FSC and SSC) into two fractions, P1 (larger sized cells) and P2 (smaller sized cells), by FACScan. (b) Cell cycle distributions of P1 and P2 fractions were analyzed by FACScan. (c) HCA2 cells at 72 hrs after IR treatment (10 Gy) were sorted by FSC and SSC as in (a) without staining with Hoechst 33342. Total RNAs from the P1 or P2 fraction were then subjected to microarray analysis. Scatter plots identified Fbxo22, WIPI, PPP2R5C, and DARC as genes that were significantly more abundant in the P1 fraction than in the P2 fraction. We confirmed that the four respective proteins were markedly induced after IR treatment. (see Figure 1c) . (a) RPE cells treated as in Figure 2a (four left panels) and 2c (four right panels) at 3 days after addition of doxycycline were stained with Hoechst 33342 and analyzed for cell cycle distribution by FACScan. (b) RPE cells expressing Dox-inducible Flag-Fbxo22 were treated with (FlagFbxo22) or without (Control) doxycycline (1 µg/ml) in the presence of Nutlin 3a (5 µM). Cells were lysed at the indicated times after the addition of Nutlin 3a and the lysates were subjected to immunoblotting using the indicated antibodies. (c) RPE cells expressing the Dox-inducible shControl and shHdm2 together with or without Flag-Fbxo22 were treated with doxycyclin (1 µg/ ml). Cells were lysed at the indicated times after the addition of doxycycline and the lysates were subjected to immunoblotting using the indicated antibodies. (a) RPE cells expressing Dox-inducible Flag-Fbxo22 were treated with or without doxycyclin (1 µg/ml) for 48 hrs, and were then treated with or without MG132 (10 µg/ml) for 1 hr. The cell lysates were subjected to immunoblotting using the indicated antibodies. (b)(c) HEK293 cells were transfected with expression plasmids for 6xMyc-p53, Flag-Fbxo22, and HA-Ub-Wt (b), HA-Ub-K48 or HA-Ub-K48R (c), and were then incubated with MG132 (20 µg/ml) for 5 hrs. Total cell lysates were subjected to immunoprecipitation with anti-p53 antibody under denaturing conditions to prevent the detection of ubiquitylation of both E3 ligase itself and p53-associated proteins. The resultant precipitates and the lysates (Input) were subjected to immunoblotting using the indicated antibodies. (a) RPE cells expressing Dox-inducible full-length Flag-Fbxo22 (Wt), the indicated C-terminal truncated mutants were incubated for 48 hrs in the presence or absence of doxycycline (1 µg/ml) and were then treated with MG132 (10 µg/ml) for 2 hrs. Cells were then harvested and the lysates were subjected to immunoprecipitation using Flag M2 affinity gel. The resultant precipitates were subjected to immunoblotting using the indicated antibodies. (b) RPE cells expressing the Dox-inducible shControl or shFbxo22 were treated with doxycycline (1 µg/ml) for 48 hrs and were then treated with MG132 (10 µg/ml) for 2 hrs. Cells were then harvested and the lysates were immunoprecipiated with either a control IgG or anti-KDM4A antibodies. The resultant precipitates were subjected to immunoblotting using the indicated antibodies. (c) RPE cells expressing the Dox-inducible wild-type KDM4A (Wt) or its mutant (H188A) were treated with or without doxycycline (1 µg/ml) for 48 hrs and then treated with MG132 (10 µg/ml)for 2 hrs. The cell lysates were immunoprecipitated with a control IgG, anti-methylated p53 (K370me2), antiacetylated p53 (K370Ac), or anti-p53 antibodies. The resultant immunoprecipitates and the lysates (Input) were subjected to immunoblotting using the indicated antibodies. (d) RPE cells as in Figure 5e were harvested at the indicated times and the lysates were subjected to immunoblotting using the indicated antibodies (see Figure 5e ). (a) RPE cells expressing the Dox-inducible wild-type KDM4A (Wt) or its mutant (H188A), together with wild-type Flag-PHF20 (Wt) or its mutant (W97A/Y103A), were incubated for 48 hrs in the presence of doxycycline (1 µg/ml) and were then treated with MG132 (10 µg/ml) for 2 hrs. The lysates were immunoprecipitated using anti-Flag M2 affinity gel. The resultant immunoprecipitates and lysates (Input) were subjected to immunoblotting using the indicated antibodies. (b) RPE cells expressing the Doxinducible shControl or shFbxo22, together with either wild-type HA-KDM4A (Wt) or its H188A mutant, and wild-type Flag-PHF20 were incubated for 48 hrs in the presence of doxycycline (1 µg/ml) and were then treated with MG132 (10 µg/ml) for 2 hrs. The lysates were immunoprecipitated using Flag M2 affinity gel and the resultant precipitates as well as lysates (Input) were subjected to immunoblotting using the indicated antibodies. (c) RPE cells expressing the Dox-inducible shControl or shPHF20 were treated with doxycycline (1 µg/ml) for 48 hrs and then with IR (6 Gy).
Lysates of cells collected at the indicated times were subjected to immunoblotting using the indicated antibodies. HCA2 cells expressing the Dox-inducible shControl and shFbxo22 were synchronized at G2 phase with RO3306 (9 µM)(Time:0), treated with 5 µM Nutlin-3a, and released into fresh medium in the presence of doxycycline (1 µg/ml) at 3 days (see Figure 6a ). Cells at the indicated times were subjected to FACS analysis HCA2 cells expressing the Dox-inducible Flag-H-RasV12 together with the shControl and shFbxo22 were treated with doxycycline (1 µg/ml). Cells, cell lysates or total RNAs at the indicated times (after addition of doxycycline) were subjected to immunoblotting using the indicated antibodies (a), an SA-β-gal assay (b), and quantitative PCR analysis using IL-6 and IL-8 primers (c). Data presented as means ±s.d. of at least three independent experiments. HCA2 cells expressing the Dox-inducible shControl and shKDM4A were synchronized at G2 phase with RO3306 (9 µM)(Time:0), treated with 5 µM Nutlin-3a, and released into fresh medium in the presence of doxycycline (1 µg/ml) at 3 days (see Figure 6a ). Cells at the indicated times were subjected to FACS analysis HCA2 cells were synchronized at G2 phase with RO3306 (9 µM)(Time:0), treated with 5 µM Nutlin-3a, and released into fresh medium at 3 days in the presence or absence (None) of 5 µM Nutlin-3a (see Figure 6a) . Cell lysates or total RNAs from cells collected at the indicated times were subjected to immunoblotting using the indicated antibodies (a) or qPCR analysis using IL-6 and IL-8 primers (b), respectively. Data presented as means ±s.d. of at least three independent experiments. HCA2 cells expressing the Dox-inducible shControl and shHdm2 were synchronized at G2 phase with RO3306 (9 µM)(Time:0), treated with 5 µM Nutlin 3a, and released into fresh medium with doxycycline (1 µg/ml) at 3 days (see Figure 6a ). Cells, cell lysates or total RNAs from cells collected at the indicated times were subjected to immunoblotting using the indicated antibodies (a), an SA-β-gal assay (b) or qPCR analysis using IL-6 and IL-8 primers (c), respectively. Data presented as means ±s.d. of at least three independent experiments. HCA2 cells (None) or cells expressing the Dox-inducible wild-type (Wt) or mutant (W97A/ Y103A) Flag-PHF20 were synchronized at G2 phase with RO3306 (9 µM)(Time: 0), treated with 5 µM Nutlin 3a, and released into fresh medium with doxycycline (1 µg/ml) at 3 days (see Figure  6a ). Cells, cell lysates or total RNAs at the indicated times (after addition of doxycycline) were subjected to immunoblotting using the indicated antibodies (a), an SA-β-gal assay (b), quantitative PCR analysis using IL-6 and IL-8 primers (c), and analysis of the cellular ROS level 
